©2024 Stanford Medicine
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Not Recruiting
Trial ID: NCT01876251
Purpose
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel
combination in patients with advanced breast cancer. Preliminary information about the
efficacy of the combination will also be collected.
Official Title
Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer
Stanford Investigator(s)
Mark Pegram
Susy Yuan-Huey Hung Professor
Allison W. Kurian, M.D., M.Sc.
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Eligibility
Inclusion Criteria:
- Diagnosis of breast cancer with evidence of a) metastatic or b) locally
recurrent/advanced disease.
Exclusion Criteria:
- Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.
Intervention(s):
drug: PF-03084014
drug: PF-03084014
drug: PF-03084014
drug: Docetaxel
drug: Docetaxel
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061